Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07048964
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:37.454424+00:00
Published At
2025-07-03T00:00:00+00:00
Record Updated At
2025-07-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Medullary Thyroid Cancer (MTC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-03"
protocolSection.identificationModule.nctId
"NCT07048964"
protocolSection.identificationModule.officialTitle
"A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Medullary Thyroid Cancer (MTC) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.